Fulgent Genetics, Inc. 8-K

What Happened
Fulgent Genetics, Inc. announced its financial results for the fiscal quarter ended March 31, 2026 via a press release dated May 1, 2026. The company also updated its investor presentation on May 1, 2026; both the press release and the presentation were furnished as Exhibits 99.1 and 99.2 to the Form 8‑K. The Form 8‑K was signed by Paul Kim, Chief Financial Officer.

Key Details

• Press release announcing quarterly financial results issued and furnished as Exhibit 99.1 (dated May 1, 2026).
• Updated investor presentation posted to Fulgent’s Investor Relations site (http://ir.fulgentgenetics.com) and furnished as Exhibit 99.2.
• The materials cover the fiscal quarter ended March 31, 2026 and were furnished under Items 2.02 (results of operations) and 7.01 (Regulation FD disclosure).
• The company states these exhibits are “furnished” (not “filed”) and therefore are not subject to certain Exchange Act liabilities or automatically incorporated by reference into other filings.

Why It Matters
This 8‑K signals that Fulgent has released its latest quarterly results and updated its investor materials — key places for investors to find revenue, earnings, guidance, and business updates. Because the Form 8‑K itself does not include the numeric results, retail investors should review the furnished press release and investor presentation on Fulgent’s IR website to see the specific financial figures and management commentary.